savolitinib

Biomarkers

Sponsors

Industry sponsors leading active biomarker-selected trials of savolitinib.

1. AstraZeneca 5
2. HUTCHMED 1

Trials

8 of 14 trials shown

1. Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

   Active, not recruiting Phase 3 AstraZeneca Started 2022Primary completion 2026-07 NCT05261399

   savolitinibosimertinib FDA EUpemetrexedcisplatincarboplatin

   Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M.

   EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung

2. Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

   Active, not recruiting Phase 3 HUTCHMED Started 2021Primary completion 2028-05 NCT05009836

   savolitinibosimertinib FDA EU

   …arrying two common EGFR mutations clearly related with the sensitivity to EGFR-TKI (i.e., exon 19 deletion, and L858R) and c-MET overexpression

   EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer

3. Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

   Recruiting Phase 2 Qingdao Central Hospital Started 2025Primary completion 2026-12 NCT07322783

   savolitinibosimertinib FDA EU

   Osimertinib Combined With Savolitinib in the Treatment of EGFR Mutated Osimertinib Resistant NSCLC With Low Copy Number MET Amplification

   EGFR exon 19 deletion / L858REGFR Positive Non-small Cell Lung Cancer, MET Amplification

4. Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

   Recruiting Phase 2 Sun Yat-sen University Started 2024Primary completion 2027-11 NCT06563999

   sunvozertinib FDAcrizotinibpralsetiniblarotrectinibsavolitinibpyrotinibdabrafenibtrametinibglecirasibensartinib

   Subjects should have a rare mutation based on NGS, including mutations of EGFR exon20ins, ROS1 fusion, RET fusion, NTRK fusion, MET 14 exon, HER2, BRAF V600E, KRAS G12C, and ALK …

   EGFR exon 20 insertionKRAS G12CBRAF V600EALK fusionROS1 fusionRET fusion or mutationNTRK1/2/3 fusionLung Cancer Stage III, Mutation

5. Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC

   Active, not recruiting Phase 2 AstraZeneca Started 2022Primary completion 2027-01 NCT05374603

   savolitinibdurvalumab

   MET Exon 14 skipping mutation, or MET overexpression (IHC 3+ in ≥70% of tumor cells), or MET amplific…

   MET exon 14 skippingLung Cancer

6. A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

   Active, not recruiting Phase 2 AstraZeneca Started 2020Primary completion 2022-12 NCT04606771

   osimertinib FDA EUsavolitinib

   …Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

   EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer

7. Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

   Active, not recruiting Phase 2 AstraZeneca Started 2019Primary completion 2024-08 NCT03778229

   osimertinib FDA EUsavolitinib

   …with EGFR TKI sensitivity and permitted in the osimertinib national label (such as either exon 19 deletion and/or L858R) which is not amenable to curative therapy.

   EGFR exon 19 deletion / L858RCarcinoma

8. AZD9291 in Combination With Ascending Doses of Novel Therapeutics

   Active, not recruiting Phase 1 AstraZeneca Started 2014Primary completion 2020-03 NCT02143466

   osimertinib FDA EUsavolitinibselumetinibdurvalumab

   …our harbours an EGFR mutation known to be associated with EGFR TKI sensitivity (including exon 19 deletion and L858R).

   EGFR exon 19 deletion / L858RAdvanced Non Small Cell Lung Cancer

No trials match these filters.